Eribulin mesylate and Constipation - a phase IV clinical study of FDA data

Summary:

Constipation is reported as a side effect among people who take Eribulin mesylate (eribulin mesylate), especially for people who are female, 40-49 old, have been taking the drug for 1 - 6 months also take Vinorelbine, and have Breast cancer metastatic.

The phase IV clinical study analyzes which people have Constipation when taking Eribulin mesylate. It is created by eHealthMe based on reports of 365 people who have side effects when taking Eribulin mesylate from the FDA, and is updated regularly.

What is Eribulin mesylate?

Eribulin mesylate has active ingredients of eribulin mesylate. eHealthMe is studying from 366 Eribulin mesylate users. Check the latest studies of Eribulin mesylate.

What is Constipation?

Constipation is found to be associated with 3,004 drugs and 4,615 conditions by eHealthMe. Check the latest studies of Constipation.

On Aug, 01, 2026

365 people reported to have side effects when taking Eribulin mesylate.
Among them, 32 people (8.77%) have Constipation.

Could Eribulin mesylate cause Constipation?

Among these 32 people:

How long have people been on Eribulin mesylate when they have Constipation? *

What is the gender of people who have Constipation when taking Eribulin mesylate? *

female: 100 %
male: 0.0 %

What is the age of people who have Constipation when taking Eribulin mesylate? *

What are other drugs people take besides Eribulin mesylate? *

What are other side effects people have besides Constipation? *

Diarrhea: 27 people, 84.38%
Dyspnea (difficult or laboured breathing): 26 people, 81.25%
Nausea (feeling of having an urge to vomit): 26 people, 81.25%
Fatigue (feeling of tiredness): 26 people, 81.25%
Back Pain: 25 people, 78.12%
Pain: 25 people, 78.12%
Fever: 25 people, 78.12%
Headache (pain in head): 24 people, 75.00%
Neuropathy Peripheral (surface nerve damage): 21 people, 65.62%
Hair Loss: 17 people, 53.12%

What are the existing conditions these people have? *

Breast Cancer Metastatic: 25 people, 78.12%
Neuropathy Peripheral (surface nerve damage): 11 people, 34.38%
Embolism Venous (embolus may pass into the arterial system): 9 people, 28.12%
Stomatitis (inflammation of mucous membrane of mouth): 7 people, 21.88%
Pain In Extremity: 7 people, 21.88%
Lower Respiratory Tract Infection: 7 people, 21.88%
Diarrhea: 7 people, 21.88%
Cellulitis (infection under the skin): 7 people, 21.88%
Insomnia (sleeplessness): 5 people, 15.62%
Upper Respiratory Tract Infection: 4 people, 12.50%

* Approximation only. Some reports may have incomplete information.

Do you take Eribulin mesylate and have Constipation?

- Check whether Constipation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Eribulin mesylate:

Eribulin mesylate (366 reports)

Constipation treatments and more:

Constipation (337,880 reports)

Browse all side effects of Eribulin mesylate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Constipation:

Constipation (3,004 drugs)

Browse all the conditions that are associated with Constipation:

Constipation (4,615 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on eribulin mesylate (the active ingredients of Eribulin mesylate) and Eribulin mesylate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.